Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study

• Autorzy: Golshahi H. , Tavasolu A. , Rezaie A. , Farhadi M.
• Języki publikacji: EN

Abstrakty

EN

Immunohistochemical expression of urokinase plasminogen activator (uPA) was studied in 37 canine malignant mammary tumours to define the relationship between their histopathological type and grade. In 29 (78.4%) cases, expression of uPA by neoplastic cells was more than 10% and in 34 samples (91.9%) uPA expression by stromal cells (fibroblasts) was more than 10%. The uPA was expressed in epithelial and myoepithelial cells of carcinomas and carcinosarcomas and mesenchymal population of carcinosarcoma, chondrosarcoma, and carcinomas arising in benign tumours. The intensity and percentage of expression of uPA by stromal cells was associated with their histological grade (P < 0.05). However, no significant relationship was detected between uPA expression by neoplastic cells (epithelial, myoepithelial, and mesenchymal cell) and histological grade. Increased expression of uPA by tumour stroma was associated with poor prognostic factors. Stromal expression of uPA could be a prognostic indicator for canine mammary tumours.

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2013
• Tom: 57
• Numer: 4
• Opis fizyczny: p.587-591,fig.,ref.

Twórcy

autor

Golshahi H.

• Department of Pathology, Faculty of Veterinary Medicine, University of Tehran, 14155-6453 Tehran, Iran

autor

Tavasolu A.

• Department of Pathology, Faculty of Veterinary Medicine, University of Tehran, 14155-6453 Tehran, Iran

autor

Rezaie A.

• Department of Pathobiology, Faculty of Veterinary Medicine, University of Shahid Chamran, 61355145 Ahvaz, Iran

autor

Farhadi M.

• Department of Haematology, Iranian Blood Transfusion Organization, 14665-1381 Tehran, Iran

Bibliografia

• 1. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J.: The urokinase type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72, 1 -22.
• 2. Angenete E., Langenskiöld M., Palmgren I., Falk P., Öresland T., Ivarsson M.L.: uPA and PAI-1 in rectal cancer - relationship to radiotherapy and clinical outcome. J Surg Res 2009, 153, 46-53.
• 3. Bailey T.R., Paulsen D.B., Sehgal I., Hosgood G.: Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs. Am J Vet Res 2006, 67, 1628-1634.
• 4. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., Astedt B.: High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 1998, 79, 588-595.
• 5. Blasi F., Carmeliet P.: uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002, 3, 932-943.
• 6. Buo L., Meling G.I., Karlsrud T.S., Johansen H.T., Aasen A.O.: Antigen levels of urokinase plasminogen activator and its receptor at the tumour-host interface of colorectal adenocarcinomas are related to tumour aggressiveness. Hum Path 1995, 26, 1133-1138.
• 7. Carmeliet P., Jain R.K.: Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
• 8. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368, 419-424.
• 9. Damjanovich L., Turzo C., Adany R.: Factors involved in the plasminogen activation system in human breast tumours. Thromb Haemost 1994, 71, 684-691.
• 10. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D.: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumour pathology. Am J Pathol 2000, 157, 1219-1227.
• 11. Duffy M.J., Duggan C.: The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem 2004, 37, 541-548.
• 12. Elston C.W., Ellis I.O.: Assessment of histological grade, In: Systemic Pathology - The Breast, edited by C.W. Elston and I.O. Ellis, Churchill and Livingstone, London, 1998, pp. 365-384.
• 13. Guo Y., Higazi A.A.R., Arakelian A., Sachais B.S., Cines D., Goldfarb R.H., Jones T.R., Kwaan H., Mazar A.P., Rabbani S.A.: A peptide derived from the non receptor binding region of urokinase plasminogen activator (uPA) inhibits tumour progression and angiogenesis and induces tumour cell death in vivo. FASEB J 2000, 14, 1400-1410.
• 14. Han B., Nakamura M., Zhou G., Ishii A., Nakamura A., Bai Y., Mori I., Kakudo K.: Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 2006, 28, 807-814.
• 15. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K.: Urokinase -type plasminogen activator system and breast cancer. Oncol Rep 2005, 14, 105-112.
• 16. Harbeck N., Kates R.E., Schmitt M., Gauger K., Kiechle M., Janicke F.: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Canc 2004, 5, 348-352.
• 17. Hildenbrand R., Schaaf A., Dorn-Beineke A., Allgayer H., Sütterlin M., Marx A., Stroebel P.: Tumour stroma is the predominant uPA, uPAR, PAI-lexpressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009, 24, 869-877.
• 18. Hundsdorfer B., Zeilhofer H.F., Bock K.P.. Dettmar P., Schmitt M., Kolki A., Pautke C., Horch H.H.: Tumour-associated urokinase -type plasminogen activator (uPA) and its inhibitor PAI -1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Cranio Maxill Surg 2005, 33, 191-196.
• 19. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G.: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
• 20. Look M.P., van Putten W.L.. Dufty M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Fernö M., Eppenberger-Castori S., Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brünner N., Duggan C., Lisboa B.W., Bendahl P.O., Quillien V., Daver A., Ricolleau G., Meijervan Gelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broët P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V., Klijn J.G., O'Higgins N., Eppenberger U., Jänicke F., Schmitt M., Foekens J.A.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94, 116-128.
• 21. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P.: Histological classification of the mammary tumours of the dog and the cat. In: World Health Organization International Histological Classification of Tumours of Domestic Animals, edited by F.I. Shulman, Armed Forces Institute of Pathology, Washington DC, 1999, pp. 16-29
• 22. Nielsen B.S., Rank F., Illemann M., Lund L.R., Danø K.: Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007, 120, 2086-2095.
• 23. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø, K.: Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001, 81, 1485-1501.
• 24. Reuning U., Magdolen V., Hapke S., Schmitt M.: Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem 2003, 384, 1119- 1131.
• 25. Santos A.A., Lopes C.C., Ribeiro J.R., Martins L.R., Santos J.C., Amorim I.F., Gärtner F., Matos A.J.: Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study. BMC Vet Res 2013, 9, doi: 10.1186/1746-6148- 9-1.
• 26. Santos A., Lopes C., Marques R.M., Amorim I., Ribeiro J., Frias C., Vicente C., Gärtner F., Matos A.: Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J 2011, 189, 43-48.
• 27. Schmitt M., Wilhelm O.G., Reuning U., Krüger A., Harbeck N., Lengyel E., Graeff H., Gänsbacher B., Kessler H., Bürgle M., Stürzebecher J., Sperl S., Magdolen V.: The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinolysis Proteol 2000, 14, 114 -132.
• 28. Schneider J., Pollan M., Tejerina A., Sanchez J., Lucas A.R.: Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. Br J Cancer 2003, 88, 96-101.
• 29. Ulisse S., Baldini E., Sorrenti S., D'Armiento M.: The urokinase plasminogen activator system: a target for ami-cancer therapy. Curr Cancer Drug Targ 2009, 9, 32-71.
• 30. Wang Y.: The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001, 21, 146- 170.

Identyfikatory

DOI

10.2478/bvip-2013-0100